Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17101400 | 1.00 | CHRM3 (1.00) | CHRM3ADRB2 | |
| SCHEMBL14199548 | 0.93 | CHRM3 (1.00) | CHRM3ADRB2 | |
| SCHEMBL14199537 | 0.92 | CHRM3 (1.00) | CHRM3ADRB2 | |
| SCHEMBL14199530 | 0.88 | CHRM3 (0.79) | CHRM3ADRB2 | |
| SCHEMBL4995831 | 0.84 | CHRM3 (0.72) | CHRM3ADRB2 | |
| SCHEMBL4995820 | 0.84 | CHRM3 (0.72) | CHRM3ADRB2 | |
| SCHEMBL5655232 | 0.83 | CHRM3 (1.00) | CHRM3ADRB2 | |
| SCHEMBL5655220 | 0.83 | CHRM3 (1.00) | CHRM3ADRB2 | |
| SCHEMBL5655228 | 0.83 | CHRM3 (1.00) | CHRM3ADRB2 | |
| SCHEMBL5650667 | 0.82 | CHRM3 (1.00) | CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556435-B1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3556435-A1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2019-10-23 | — | — | EP | disclosed |
| US-10336725-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2019-07-02 | — | — | US | disclosed |
| WO-2018108089-A1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | 北京硕佰医药科技有限责任公司 | 2018-06-21 | — | — | WO | disclosed |
| US-20180162838-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2018-06-14 | — | — | US | disclosed |
| US-20080090873-A1 | Sulfonamide derivatives | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090873-A1 | Sulfonamide derivatives | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336725-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | CHRM3 167/4885ADRB2 147/4885 |
| US-20080090873-A1 | Sulfonamide derivatives | SULT2A1, SULT1A1, STS | CHRM3 2453/4885ADRB2 2763/4885 |
| US-20180162838-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | CHRM3 167/4885ADRB2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.